The CHORUS (cerivastatin in heart outcomes in renal disease: Understanding survival) protocol: A double-blind, placebo-controlled trial in patients with ESRD

American Journal of Kidney Diseases

Volumn 37, Issue 1, 2001, Pages S48-S53

  Keane, William F ^a,b,c   Brenner, Barry M ^a,b,c   Mazzu, Arthur ^a,b,c   Agro, Albert ^a,b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Cardiovascular disease (CVD); End stage renal disease (ESRD); Hemodialysls; HMG CoA reductase inhibitors; Lipids

Indexed keywords

C REACTIVE PROTEIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOSTATIN M; PLACEBO; TROPONIN I; TROPONIN T;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTICENTER STUDIES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 0035153751     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.20739     Document Type: Article

References (22)

1. Long-term outcome of dialysis patient in the United States with coronary revascularization procedures
2. Analysis, of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias
3. Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis
4. Coronary heart disease: Reducing the risk: The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view
5. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis
6. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other nontraditional cardiac risk factors
7. Lipids and progressive renal disease: The cardio-renal link
8. Lipids and the kidney
9. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
10. Lipids in progression of renal disease
11. Simvastatin therapy for hypercholesterolenic patients with nephrotic syndrome or significant proteinuria
12. Effects of hypercholesterolemia on renal hemodynamics: Study in patients with nephrotic syndrome
13. A pooled efficacy analysis of cerivastalin in the treatment of primary hyperlipidemia
14. Efficacy and safety of cerivastatin 0.2 mg and 0.4 mg in patients with primary hypercholesterolemia: A multinational, randomized, double-blind study
15. Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance
16. Mild renal impairment does not alter the pharmacokinetics of cerivastatin in normocholesterolemic adults
17. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
18. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolemia. Hyperlipidaemia in diabetes mellitus investigators
19. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIB/III studies
20. Effect of cervastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis and the lesional composition in the plaques of WHHL rabbits
21. An HMG-CoA reductase inhibitor (cervastatin) suppresses accumulation of macrophages expressing matrix metalloproleinases and tissue factor in atheroma of WHHL rabbits